FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for XTANDI (enzalutamide) from Astellas Pharma US to modify/expand its label for prostate cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Non-metastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

SUPPL AP for XTANDI (ENZALUTAMIDE)